Du HaoChen, vice president of AstraZeneca China, is about to join Baiji Shenzhou
On November 5, Wu Xiaobin, President of Baiji Shenzhou, announced to the employees that Du HaoChen will officially join Baiji Shenzhou as the head of broad market and work in Shanghai from November 18, 2021. Du HaoChen is currently the vice president of AstraZeneca China and the head of the county business department. On Monday, Lai Minglong, general manager of AstraZeneca China, announced a personnel change in the county business to the employees. Du HaoChen decided to leave the company for personal reasons. The last working day is November 17.
This text is a result of machine translation.
Briefing Jan 19, 2022 06:12 PM
· Healthcare
Sinopharm capital officially changed its name to "Jianyi capital" and continued to build a distinctive "CVC + IVC" pharmaceutical equity investment institution
In depth
Briefing Jan 18, 2022 11:23 AM
· Healthcare
Focusing on the digital transformation of bone and joint disease treatment, Aiqiao medical completed tens of millions of yuan of PREA round financing
Briefing Jan 18, 2022 11:16 AM
· Healthcare
Surgical robot enterprises have completed hundreds of millions of yuan of round B financing and accelerated the comprehensive commercial layout
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Jan 18, 2022 11:12 AM
· Healthcare
Micro Asia Medical, a minimally invasive vascular intervention robot enterprise, completed tens of millions of yuan of round a financing
Briefing Jan 17, 2022 10:27 AM
· Healthcare
The micro structure workshop completed a round of financing of 250 million yuan to build an international R & D headquarters for PHA, a new generation of biodegradable materials
Briefing Jan 17, 2022 10:21 AM
· Healthcare
FDA approved Suoyuan biology to carry out the first international multicenter clinical trial under the guidance of biomarkers in the field of CNS
Briefing Jan 17, 2022 10:13 AM
· Healthcare
AI + RNA start-up Revir xigravel technology received tens of millions of dollars in pre-A round of financing
Briefing Jan 17, 2022 10:09 AM
· Healthcare
Jialiang medical announced the completion of round B financing of hundreds of millions of yuan
Briefing Jan 13, 2022 10:05 AM
· Healthcare
West Lake Omei won hundreds of millions of yuan of pre-A round of financing to help clinical diagnosis and AI new drug research and development based on proteome big data
In depth
Healthcare
Zhaoke Ophthalmology Partners with Yidu Tech's HLT on Ophthalmic Clinical Research
On 16 December, Zhaoke Ophthalmology (SEHK: 6622) and HappyLife Technology ("HLT"), an affiliate of Yidu Tech Inc. ("Yidu Tech", SEHK: 2158), announced to have signed a Letter of Intent with an objective to accelerate the development of innovative clinical research programs for the Chinese ophthalmic market.
Dec 16, 2021 02:04 PM
Briefing Jan 12, 2022 09:28 AM
· Healthcare
Zhenge biology obtained US $100 million in round C financing, led by Goldman Sachs and Sofina
Briefing Jan 10, 2022 09:00 PM
· Healthcare
Bristol Myers Squibb entered the development of IPSC derived allogeneic cell therapy with more than US $3 billion
Briefing Jan 10, 2022 11:16 AM
· Healthcare
Lanjing microorganism completed a total of RMB 1.5 billion of Series B financing and accelerated the implementation of the "T-type" development strategy
Briefing Jan 10, 2022 09:37 AM
· Healthcare
Synthetic biology enterprise Lanjing microorganism completed a total of 1.5 billion yuan of Series B financing
See more
Read next
Insight
Technology
Another Look at China's Semiconductor Manufacturing Equipment Industry
Jan 19, 2022 02:58 PM
Insight
In depth
Automotive
Carnex: A Growing Life Cycle Used EV Platform Founded by Tesla Enthusiasts
Jan 19, 2022 07:59 AM
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.